pharma · Duchenne muscular dystrophy (DMD) · JAK2V617F-positive high-risk Polycythemia Vera
ITALFARMACO S.P.A
Italfarmaco S.p.A.
ITALFARMACO S.P.A clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cinisello Balsamo, IT
- Founded
- 1938
- Employees
- 629
- Programs
- 7
- Drugs
- 17
- Patents
- 0
ITALFARMACO S.P.A projects
7 ClinicalTrials.gov programs sponsored by ITALFARMACO S.P.A.
ITALFARMACO S.P.A has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
DSC/08/2357/32
Italfarmaco S.p.A.
JAK2V617F-positive high-risk Polycythemia Vera
1 trial -
DSC/14/2357/50
Italfarmaco S.p.A.
Duchenne muscular dystrophy (DMD)
1 trial -
ITF2357
Italfarmaco S.p.A.
Duchenne Muscular Dystrophy (DMD)
1 trial -
DSC/11/2357/44
Italfarmaco S.p.A.
Chronic myeloproliferative neoplasm
1 trial -
ITF2357
Italfarmaco S.p.A.
Duchenne muscular dystrophy (DMD)
1 trial -
ITF2357-60
Italfarmaco S.p.A.
Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI
1 trial -
EFFI2021/01
Italfarmaco S.p.A.
Female contraception.
1 trial
Frequently asked questions
How many clinical projects does ITALFARMACO S.P.A have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.